Investigating a new treatment for heart disease caused by thickened heart muscle.
C-type natriuretic peptide in hypertrophic cardiomyopathy
This study is looking at a new treatment using a special version of a heart-related protein called CNP to see if it can help people with hypertrophic cardiomyopathy (HCM) by reducing heart muscle thickening and improving their condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11000261 on NIH RePORTER |
What this research studies
This research focuses on understanding how C-type natriuretic peptide (CNP) can be used to treat hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick. The study aims to explore the potential of a CNP analog called C53, which may help reduce fibrosis, a key factor that worsens HCM. By using innovative methods to deliver C53 effectively, the researchers hope to determine if it can prevent or reverse fibrosis in patients with HCM. This could lead to new therapeutic options for individuals suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly those experiencing symptoms related to cardiac fibrosis.
Not a fit: Patients without hypertrophic cardiomyopathy or those whose condition is not related to cardiac fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that effectively reduces heart muscle fibrosis in patients with hypertrophic cardiomyopathy.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting natriuretic peptides, suggesting potential for success in this novel application.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Armstrong, David William John — Vanderbilt University Medical Center
- Study coordinator: Armstrong, David William John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.